The US Specialty Pharmacy Landscape in 2026

How the US specialty pharmacy market is structured in 2026: PBM-owned giants, the rise of health-system pharmacies, private-equity-backed independents, and what it means for manufacturers.

Published July 21, 2026

Specialty Pharmacy

The US specialty pharmacy market in 2026 is a $293 billion, highly concentrated industry in the middle of a structural shift. Pharmacies dispensed an estimated $293.4 billion in specialty medications in 2025 — up 9.6% from 2024 — and the three largest players, all owned by vertically integrated PBM parents, captured two-thirds of that revenue, according to Drug Channels Institute. Around that concentrated core, two segments are gaining ground: hospital and health-system specialty pharmacies, now 28% of all accredited locations, and a small group of well-capitalized independents that private equity is valuing aggressively — most visibly in the roughly $7 billion PANTHERx Rare deal announced in July 2026. Here is how the landscape breaks down and what it means for manufacturers planning distribution networks.

Market size and concentration

Key figures from Drug Channels Institute’s 2026 analysis of the 2025 market:

Metric	2025 figure
Specialty dispensing revenue (retail, mail, LTC, specialty pharmacies)	$293.4 billion, +9.6% vs. 2024
Share of revenue held by the three largest specialty pharmacies	About two-thirds
Accredited specialty pharmacy locations	More than 1,900 (+3% vs. 2024; over 5x the 2015 count)
Health-system-operated accredited locations	553, up from 106 in 2017
Share of exclusive-network specialty products accessible to PBM-owned pharmacies	About 20%

Two things stand out. First, accreditation has proliferated while economics have not: locations keep multiplying, but revenue remains concentrated in a handful of vertically integrated organizations. Second, specialty’s share of total pharmacy prescription revenue — just under 40% — has plateaued after a decade of relentless growth, even as absolute dollars keep climbing.

The PBM-owned core

Three pharmacies anchor the market, each tied to one of the big three PBMs:

Accredo Specialty Pharmacy — part of Evernorth Health Services (The Cigna Group), alongside the Express Scripts PBM.
CVS Specialty — CVS Health’s specialty arm, affiliated with the Caremark PBM.
Optum Specialty Pharmacy — UnitedHealth Group’s specialty pharmacy within Optum Rx, with a dedicated rare-disease unit in Optum Frontier Therapies.

Their dominance is reinforced from both directions: payers steer specialty prescriptions to affiliated pharmacies, and specialty dispensing in turn generated more than a third of PBMs’ total gross profits in 2025, per Drug Channels. For manufacturers, these pharmacies are unavoidable for broad-access retail specialty brands — but they hold access to only about 20% of specialty products with exclusive dispensing networks, which is precisely where the rest of the market competes.

The payer-integrated second tier

Below the big three sits a tier of insurer- and retailer-owned specialty pharmacies, each leveraging a captive book of covered lives:

AcariaHealth — Centene’s in-house specialty pharmacy.
BioPlus Specialty Pharmacy — part of Elevance Health’s CarelonRx, which has also added Kroger Specialty Pharmacy and infusion assets to build out its platform.
CenterWell Specialty Pharmacy — Humana’s pharmacy arm, expanding into direct-to-patient specialty dispensing.
Walgreens Specialty Pharmacy — the former AllianceRx business, now under private ownership after Sycamore Partners closed its take-private of Walgreens Boots Alliance in August 2025 and split the company into five standalone entities.

The health-system surge

The fastest-growing segment is hospitals and health systems dispensing specialty drugs through their own pharmacies. Accredited health-system locations grew from 106 in 2017 to 553 in 2025 — 28% of all accredited specialty pharmacies. The drivers are structural: 340B program economics, manufacturer restrictions on external contract pharmacies pushing systems to build in-house capacity, and self-insured systems steering their own employees’ prescriptions internally.

An ecosystem of enablers has grown up around this shift. Shields Health Solutions, which partners with health systems to build and run specialty pharmacy programs, emerged from the Walgreens breakup as a standalone company under Sycamore Partners. Clearway Health, a Boston Medical Center spinout, plays a similar role. Drug Channels notes that both Cigna and UnitedHealth have made significant investments in businesses serving health-system specialty pharmacies — a sign that even the incumbents are hedging toward this channel.

Independents and the rare-disease specialists

Independent pharmacies remain the largest category of accredited locations but a minority of revenue. The winners in this segment are larger, private-equity-backed operators with strong positions in limited-distribution and rare-disease networks:

PANTHERx Rare — the rare-disease specialist that Centene sold in 2022; in July 2026, a Warburg Pincus-led group (reportedly with the Abu Dhabi Investment Authority) agreed to acquire a controlling interest in a deal valued at approximately $7 billion including debt.
Senderra Specialty Pharmacy and Soleo Health — cited by Drug Channels alongside PANTHERx as PE-backed independents gaining ground.

A broader bench of independents competes on limited-distribution drug (LDD) access and high-touch clinical models, including Amber Specialty Pharmacy (Hy-Vee), AnovoRx, Biologics by McKesson, Onco360, Orsini Specialty Pharmacy, and US Bioservices (Cencora). Because manufacturers of orphan and ultra-orphan products often prefer narrow networks of one to three pharmacies, these players hold exclusive positions the PBM giants cannot reach — the flip side of that 20% access statistic.

The deal market around this segment stayed hot through 2026: beyond PANTHERx, Peak Rock Capital completed its acquisition of specialty pharmacy services company Asembia, whose annual summit remains the industry’s central gathering.

What it means for manufacturers

Network design is now a three-channel decision. A specialty launch in 2026 must weigh PBM-owned pharmacies (payer pull-through, broad access), independents (LDD control, data partnership, high-touch service), and health-system pharmacies (site-of-care alignment, 340B exposure) — and most brands will need a deliberate mix rather than a default.

Expect your pharmacy partners’ ownership to change. Between the Walgreens breakup, the PANTHERx and Asembia transactions, and continued PE interest, ownership turnover is now a normal contract-lifecycle event. Build change-of-control notice and data-portability terms into network agreements.

Watch the health-system channel closely. Whether it is a threat or an opportunity depends on your product: for provider-administered and clinic-adjacent therapies, in-house health-system pharmacies can improve speed to therapy; for 340B-sensitive brands, they complicate pricing strategy. Either way, the channel’s growth from 106 to 553 accredited locations in eight years makes ignoring it untenable.

For a manufacturer selecting partners, the practical advice is the same as ever, only more urgent: define what your product needs from a pharmacy — reach, exclusivity, clinical wraparound, or data — and match the segment to the need before comparing individual vendors.